GPR39 as a Therapeutic Target in Vascular Cognitive Impairment Dementia – The University of Arizona Health Sciences |

Please join Dr. Nabil Alkayed, Professor of Anesthesiology & Perioperative Medicine, Neurology, Neurological Surgery, Cardiovascular Medicine and Physiology & Pharmacology at Oregon Health & Science University (OHSU) for a presentation over breakfast.

Dr. Alkayeds presentation will review human and experimental evidence for the role of eicosanoid signaling in aging-related cognitive impairment and dementia (VCID), specifically focusing on the role of P450 eicosanoids and the newly discovered G protein-coupled receptor 39 (GPR39). Evidence supporting the role of GPR39 in VCID in humans and animal models sets the stage for therapeutic development and other clinical applications.

Excerpt from:
GPR39 as a Therapeutic Target in Vascular Cognitive Impairment Dementia - The University of Arizona Health Sciences |

Related Posts